| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | 100,9 k € | +27.3% | 79,3 k € | -33.4% | 119,0 k € | +66.6% | 71,4 k € | -47.8% | 136,8 k € | |||||||||||
| Gross margin | 125,4 k € | +13.8% | 110,2 k € | +10.5% | 99,8 k € | +119.0% | 45,6 k € | -71.8% | 161,3 k € | +24.3% | 129,8 k € | -9.8% | 144,0 k € | +59.3% | 90,4 k € | +19.3% | 75,8 k € | +28.0% | 59,2 k € | +56.3% | 37,9 k € | +170.6% | 14,0 k € | -76.6% | 60,0 k € | +205.6% | 19,6 k € | -60.0% | 49,0 k € | |
| EBITDA | 123,7 k € | +13.0% | 109,5 k € | +11.0% | 98,6 k € | +119.3% | 45,0 k € | -72.0% | 160,4 k € | +23.8% | 129,5 k € | -9.9% | 143,7 k € | +59.5% | 90,1 k € | +19.4% | 75,5 k € | +28.3% | 58,8 k € | +55.9% | 37,7 k € | +184.2% | 13,3 k € | -77.8% | 59,9 k € | +208.4% | 19,4 k € | -60.2% | 48,7 k € | |
| Operating profit | 112,7 k € | +15.2% | 97,8 k € | +7.7% | 90,8 k € | +133.6% | 38,9 k € | -74.8% | 154,0 k € | +25.5% | 122,6 k € | -9.5% | 135,5 k € | +67.5% | 80,9 k € | +25.4% | 64,5 k € | +40.8% | 45,8 k € | +62.5% | 28,2 k € | +281.0% | 7,4 k € | -86.1% | 53,3 k € | +307.7% | 13,1 k € | -64.7% | 37,1 k € | |
| Profit/loss | 72,8 k € | +2.1% | 71,4 k € | -6.7% | 76,5 k € | +170.2% | 28,3 k € | -73.4% | 106,5 k € | +25.2% | 85,1 k € | -8.3% | 92,8 k € | +86.7% | 49,7 k € | +20.7% | 41,2 k € | +64.9% | 25,0 k € | +17.1% | 21,3 k € | +282.7% | 5,6 k € | -85.2% | 37,7 k € | +297.0% | 9,5 k € | -62.8% | 25,5 k € | |
| Equity | 519,4 k € | -3.6% | 538,6 k € | +4.4% | 516,2 k € | +5.0% | 491,8 k € | +5.9% | 464,3 k € | +16.9% | 397,2 k € | +26.9% | 312,9 k € | +41.6% | 220,9 k € | +28.4% | 172,0 k € | +31.5% | 130,8 k € | +23.6% | 105,9 k € | +25.2% | 84,5 k € | +7.1% | 79,0 k € | +91.5% | 41,2 k € | +30.0% | 31,7 k € | |
| Total assets | 549,1 k € | -6.6% | 587,9 k € | +6.9% | 550,1 k € | +2.1% | 538,7 k € | +2.4% | 526,3 k € | +12.5% | 467,9 k € | +15.4% | 405,6 k € | +27.2% | 318,9 k € | +15.9% | 275,1 k € | +9.8% | 250,6 k € | +63.4% | 153,4 k € | +70.6% | 89,9 k € | +6.1% | 84,7 k € | +73.8% | 48,7 k € | +24.6% | 39,1 k € | |
| Cash | 111,7 k € | -21.9% | 143,0 k € | +23.2% | 116,1 k € | -9.2% | 127,8 k € | -67.8% | 396,8 k € | +22.5% | 323,9 k € | +31.9% | 245,6 k € | +32.0% | 186,1 k € | +39.9% | 133,0 k € | +71.9% | 77,4 k € | +273.9% | 20,7 k € | -64.3% | 57,9 k € | +64.1% | 35,3 k € | +92.3% | 18,4 k € | -17.6% | 22,3 k € | |
| Debts | 29,6 k € | -39.8% | 49,3 k € | +45.0% | 34,0 k € | -27.6% | 46,9 k € | -21.7% | 59,9 k € | -15.3% | 70,7 k € | -22.8% | 91,6 k € | -6.5% | 98,0 k € | -3.7% | 101,8 k € | -15.0% | 119,7 k € | +151.9% | 47,5 k € | +850.2% | 5,0 k € | -12.9% | 5,7 k € | -23.5% | 7,5 k € | +1.5% | 7,4 k € | |
Private limited company · Destelbergen · incorporated on 02/12/2009
Private limited company profitable and well capitalised. Cash position declining (-21.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Joos Clinical Projects is a Private limited company incorporated in 2009. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Destelbergen.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.